Actinium Pharmaceuticals Files 8-K on Director/Officer Changes
Ticker: ATNM · Form: 8-K · Filed: Nov 27, 2024 · CIK: 1388320
| Field | Detail |
|---|---|
| Company | Actinium Pharmaceuticals, Inc. (ATNM) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, management-change, filing
Related Tickers: ACTM
TL;DR
Actinium Pharma (ACTM) filed an 8-K detailing board/exec changes & shareholder votes.
AI Summary
Actinium Pharmaceuticals, Inc. filed an 8-K on November 27, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders. The company is incorporated in Delaware and its principal executive offices are located at 100 Park Ave., New York, NY.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and governance can introduce uncertainty, but the filing itself doesn't indicate immediate financial distress.
Key Players & Entities
- Actinium Pharmaceuticals, Inc. (company) — Registrant
- November 27, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 100 Park Ave., 23rd Floor, New York, NY 10017 (address) — Principal Executive Offices
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the provided text.
Who are the departing directors or officers?
The filing states that there was a departure of directors or certain officers, but the names of these individuals are not specified in the provided text.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of certain officers, but their names are not detailed in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes that there are compensatory arrangements for certain officers, but the specifics of these arrangements are not included in the provided text.
What is the SIC code for Actinium Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Actinium Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-11-27 16:30:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ATNM NYSE American Indi
Filing Documents
- ea0222950-8k_actinium.htm (8-K) — 29KB
- 0001213900-24-103498.txt ( ) — 200KB
- atnm-20241127.xsd (EX-101.SCH) — 3KB
- atnm-20241127_lab.xml (EX-101.LAB) — 33KB
- atnm-20241127_pre.xml (EX-101.PRE) — 22KB
- ea0222950-8k_actinium_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Class II Directors On November 27, 2024, Actinium Pharmaceuticals, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). As previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 5, 2024 (the "Proxy board of directors (the "Board") nominated each director for re-election at the Annual Meeting. At the Annual Meeting, each of Sandesh Seth and Jeffrey W. Chell was elected as a Class II director of the Board to serve for a term expiring at the Company's 2027 annual meeting of stockholders.
07 Submission of Matters to a Vote of
Item 5.07 Submission of Matters to a Vote of Security Holders. A total of 19,724,287 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), were present in person or represented by proxy at the Annual Meeting. As of the close of business on October 29, 2024, the record date for the Annual Meeting, there were 31,195,891 shares of the Company's Common Stock issued and outstanding, with each share entitled to one vote. The matters described below were submitted to a vote of the holders of the Company's Common Stock at the Annual Meeting. Each proposal is described in detail in the Company's Proxy Statement. All proposals were approved by the Company's stockholders at the Annual Meeting. (1) To elect each of Sandesh Seth and Jeffrey W. Chell as a Class II director to serve for a three-year term that expires at the 2027 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal: Director For Withhold Broker Non-Votes Sandesh Seth 8,009,178 2,395,536 9,319,573 Jeffrey W. Chell 6,500,964 3,685,528 9,537,795 (2) To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 18,674,565 819,550 230,172 N/A For more information about the foregoing proposals, see the Proxy Statement, the relevant portions of which are incorporated herein by reference. The results reported above are final voting results. No other matters were considered or voted upon at the meeting. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Actinium Pharmaceuticals, Inc. Date: November 27, 2024 /s/ Sandesh Seth Name: Sandesh Seth Title: Chairman and Chief Executive Officer 2